Literature DB >> 35070121

Juvenile trabecular ossifying fibroma: Immunohistochemical expression of MDM2, CDK4 and p53 compared to conventional ossifying fibroma.

Nikolaos G Nikitakis1, Maria Georgaki1, Stavroula Merkourea1, Risa Chaisuparat2, Gary Warburton3, Marcio A Lopes4, John C Papadimitriou5, Robert A Ord3.   

Abstract

BACKGROUND: Juvenile ossifying fibroma (JOF) is an uncommon benign fibro-osseous lesion of the craniofacial skeleton; compared to conventional ossifying fibroma (OF), JOF is characterized by local aggressiveness and propensity for recurrence. The biologic basis for this different biologic behavior between JOF and OF remains elusive. The aim of this study was to evaluate the immunohistochemical expression of MDM2, CDK4 and p53, molecules associated with bone oncogenesis, in the trabecular variant of JOF.
MATERIAL AND METHODS: The study material consisted of five cases of trabecular JOF, affecting three male and two female patients with a mean age of 11.8 years. Three cases arose in the maxilla and two in the mandible. All cases were initially treated by enucleation; two cases recurred necessitating more aggressive treatment. Immunohistochemical study of MDM2, CDK4 and p53 was performed in all cases, as well as in five control cases of conventional OF.
RESULTS: CDK4 positivity was noted in all JOF cases; the staining pattern was diffuse and strong in 4 cases and focal and weak in one case. In contrast, 4 out of 5 cases of OF were weakly and focally CDK4 positive, the remaining one being negative. Immunostaining for MDM2 was observed in 3 JOF cases; all OF were MDM2 negative. All cases of OF and JOF were negative for p53, except for one focally positive JOF case.
CONCLUSIONS: CDK4 and MDM2 expression in the trabecular variant of JOF is higher compared to conventional OF. In contrast, p53 expression is almost universally negative in JOF and OF. Despite some overlapping features, differential expression patterns of proteins involved in bone oncogenesis can elucidate the pathogenesis and may facilitate accurate diagnosis and prediction of behavior of bone tumors in the craniofacial region. Key words:Juvenile ossifying fibroma, trabecular variant, conventional ossifying fibroma, MDM2, CDK4, p53. Copyright:
© 2022 Medicina Oral S.L.

Entities:  

Year:  2022        PMID: 35070121      PMCID: PMC8760962          DOI: 10.4317/jced.59116

Source DB:  PubMed          Journal:  J Clin Exp Dent        ISSN: 1989-5488


  29 in total

1.  Clinicopathological and immunohistochemical analysis of twenty-five head and neck osteosarcomas.

Authors:  Ademar Takahama Junior; Fábio de Abreu Alves; Clóvis Antonio Lopes Pinto; André Lopes Carvalho; Luiz Paulo Kowalski; Márcio Ajudarte Lopes
Journal:  Oral Oncol       Date:  2003-07       Impact factor: 5.337

2.  The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma.

Authors:  Abberly Lott Limbach; Mark W Lingen; James McElherne; Heather Mashek; Carrie Fitzpatrick; Elizabeth Hyjek; Reza Mostofi; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2020-02-05

Review 3.  P53 and prognosis: new insights and further complexity.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

4.  Juvenile ossifying fibroma. An analysis of 33 cases with emphasis on histopathological aspects.

Authors:  P J Slootweg; A K Panders; R Koopmans; P G Nikkels
Journal:  J Oral Pathol Med       Date:  1994-10       Impact factor: 4.253

5.  Amplification and protein expression of chromosome 12q13-15 genes in osteosarcomas of the jaws.

Authors:  M A Lopes; N G Nikitakis; R A Ord; J Sauk
Journal:  Oral Oncol       Date:  2001-10       Impact factor: 5.337

6.  Proliferative, apoptotic and angiogenic potentials in jaws and long bones osteosarcomas: a comparative immunohistochemical study.

Authors:  Salam N Jawad; Bashar H Abdullah
Journal:  J Oral Pathol Med       Date:  2010-08-03       Impact factor: 4.253

7.  p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.

Authors:  F Lonardo; T Ueda; A G Huvos; J Healey; M Ladanyi
Journal:  Cancer       Date:  1997-04-15       Impact factor: 6.860

Review 8.  Cell cycle regulatory functions of the human oncoprotein MDM2.

Authors:  Swati Palit Deb
Journal:  Mol Cancer Res       Date:  2003-12       Impact factor: 5.852

Review 9.  Putting p53 in Context.

Authors:  Edward R Kastenhuber; Scott W Lowe
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.